文献速递类风湿关节炎

BRASS注册研究中类风湿关节炎的数据驱动患者聚类与差异临床结局

Data-Driven Patient Clustering and Differential Clinical Outcomes in the Brigham and Women's Rheumatoid Arthritis Sequential Study Registry.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2021-03-13

该研究对BRASS注册队列中1443例RA患者的142个变量进行主成分分析和K-means聚类,识别出5个患者表型,这些表型在2年随访中表现出不同的临床结局轨迹。结果提示数据驱动的患者分型可作为支持RA个性化医疗的工具,但需在独立数据集中验证。

要点

  • 基于142个变量提取41个主成分,解释77%的累积方差,聚类出5个RA表型。
  • 5个表型在疾病活动度、共病模式、RA病程及医疗利用等方面存在差异。
  • 不同表型在2年随访中呈现不同的临床结局轨迹。

核心结论

  • 数据驱动分析识别出5个 distinct 的RA表型,提示患者分型有潜力支持个性化医疗。

研究设计与样本

  • 单中心前瞻性观察性注册队列BRASS,纳入1443例患者,分析142个变量。
  • 采用主成分分析降维,以特征值>1、累积方差和可解释性确定主成分数,再用K-means聚类。
  • 比较各聚类2年内的纵向临床结局。

主要发现

  • 41个主成分解释了数据集77%的累积方差。
  • 聚类1:RA疾病活动度/多病负担较低,RA病程较短,共病发生率较低。
  • 聚类2:RA疾病活动度/多病负担较低,RA病程较长,感染、精神共病和医疗利用较多。
  • 聚类3:RA疾病活动度/多病负担中等,神经共病较多。
  • 聚类4:RA疾病活动度/多病负担较高,RA病程较短,代谢共病较多,BMI较高。

临床怎么用

  • 数据驱动的患者分型有助于识别具有不同疾病轨迹和共病模式的RA亚群,为个体化治疗提供参考。

局限性

  • 研究为单中心注册队列,结果需在独立数据集中验证(验证正在进行中)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To use unbiased, data-driven, principal component (PC) and cluster analysis to identify patient phenotypes of rheumatoid arthritis (RA) that might exhibit distinct trajectories of disease progression, response to treatment, and risk for adverse events. METHODS: Patient demographic, socioeconomic, health, and disease characteristics recorded at entry into a large, single-center, prospective observational registry cohort, the Brigham and Women's Rheumatoid Arthritis Sequential Study (BRASS), were harmonized using PC analysis to reduce dimensionality and collinearity. The number of PCs was established by eigenvalue >1, cumulative variance, and interpretability. The resulting PCs were used to cluster patients using a K-means approach. Longitudinal clinical outcomes were compared between the clusters over 2 years. RESULTS: Analysis of 142 variables from 1,443 patients identified 41 PCs that accounted for 77% of the cumulative variance in the data set. Cluster analysis distinguished 5 patient clusters: 1) less RA disease activity/multimorbidity, shorter RA duration, lower incidence of comorbidities; 2) less RA disease activity/multimorbidity, longer RA duration, more infections, psychiatric comorbidities, health care utilization; 3) moderate RA disease activity/multimorbidity, more neurologic comorbidity; 4) more RA disease activity/multimorbidity, shorter RA duration, more metabolic comorbidity, higher body mass index; 5) more RA disease activity/multimorbidity, longer RA duration, more hepatic, orthopedic comorbidity and RA-related surgeries. The clusters exhibited differences in clinical outcomes over 2 years of follow-up. CONCLUSION: Data-driven analysis of the BRASS registry identified 5 distinct phenotypes of RA. These results illustrate the potential of data-driven patient profiling as a tool to support personalized medicine in RA. Validation in an independent data set is ongoing.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Curtis JR, Weinblatt M, Saag K, et al. Data-Driven Patient Clustering and Differential Clinical Outcomes in the Brigham and Women's Rheumatoid Arthritis Sequential Study Registry. Arthritis Care Res (Hoboken). 2021. PMID: 33002337. doi:10.1002/acr.24471

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。